Version 2 2021-02-15, 13:06Version 2 2021-02-15, 13:06
Version 1 2021-02-02, 19:07Version 1 2021-02-02, 19:07
journal contribution
posted on 2021-02-15, 13:06authored byKeri A. Tallman, Luke B. Allen, Korinne B. Klingelsmith, Allison Anderson, Thiago C. Genaro-Mattos, Károly Mirnics, Ned A. Porter, Zeljka Korade
Mouse
brain contains over 100 million neuronal, glial, and other
support cells. Developing neurons and astrocytes synthesize their
own cholesterol, and disruption of this process can occur by both
genetic and chemical mechanisms. In this study we have exposed cultured
murine neurons and astrocytes to six different prescription medications
that cross the placenta and blood–brain barriers and analyzed
the effects of these drugs on cholesterol biosynthesis by an LC–MS/MS
protocol that assays 14 sterols and 7 oxysterols in a single run.
Three antipsychotics (haloperidol, cariprazine, aripiprazole), two
antidepressants (trazodone and sertraline), and an antiarhythmic (amiodarone)
inhibited one or more sterol synthesis enzymes. The result of the
exposures was a dose-dependent increase in levels of various sterol
intermediates and a decreased level of cholesterol in the cultured
cells. Four prescription medications (haloperidol, aripiprazole, cariprazine,
and trazodone) acted primarily on the DHCR7 enzyme. The result of
this exposure was an increase in 7-dehydrocholesterol in neurons and
astrocytes to levels that were comparable to those found in cultured
neurons and astrocytes from transgenic mice that carried a Dhcr7 pathogenic mutation modeling the neurodevelopmental
disorder Smith–Lemli–Opitz syndrome.